Onco-Move and OnTrack resulted in less decline in cardiorespiratory fitness ( P < .001 ) , better physical functioning ( P .001 ) , less nausea and vomiting ( P = .029 and .031 , respectively ) and less pain ( P = .003 and .011 , respectively ) compared with UC .